Early final week, AbbVie was on each healthcare funding banker’s record. However with two fast deal bulletins below its belt in simply six days, AbbVie might have reworked its pipeline in most cancers and neurology and satiated its deal-making starvation.
The Chicago-area firm, greatest identified for promoting Botox and immune-disease drug Humira, introduced on Thursday of final week it would pay $10.1 billion for biotech ImmunoGen. On Wednesday, it adopted up with the acquisition of Cerevel Therapeutics for $8.7 billion.
Copyright ©2023 Dow Jones & Firm, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
